HR Execs on the Move

Adicet Bio

www.adicetbio.com

 
Adicet Bio, Inc. is a publicly held biotechnology company (Nasdaq: ACET) discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like targeting moieties to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.adicetbio.com
  • 1000 Bridge Parkway
    Redwood City, CA USA 94065
  • Phone: 650.503.9095

Executives

Name Title Contact Details
Amy Locke
Vice President and Head of Human Resources Profile

Similar Companies

Leap Therapeutics

Leap is developing novel drugs to change the practice of cancer medicine

Adjuvance Technologies

Helping protect life through fundamental breakthroughs in vaccine adjuvant design and manufacturing.

Home Advantage

Home Advantage is a Herndon, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

IFM Therapeutics

At IFM Therapeutics, LLC, we work to improve the lives of patients with inflammatory disorders and cancer by developing transformative medicines that precisely target the innate immune system, the body`s first line of immunological response and an essential component of immune function.

Apogee Therapeutics

Apogee Therapeutics is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and other inflammatory and immunology indications with high unmet need. Apogee`s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. The company`s two most advanced programs are APG777 and APG808, which are being initially developed for the treatment of AD and COPD, respectively. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today`s standard of care.